Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model.

Front Immunol · 2021 · PMC8350740 · PMID 34381456

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Although a marginally significant increase was observed with the Mit-A single treatment compared to the control and αPD-L1 treatment groups, an overall decrease in the g-MDSC subpopulation was observed when αPD-L1 was combined with Mit-A ( Figure 5A ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.